Application of Tumor Markers SCC-Ag, CEA, and TPA in Patients with Cervical Precancerous Lesions

Abstract

Background: To determine the potential clinical utility of tumor markers CEA, TPA, and SCC-Ag for early detection of cervical precancerous lesions. Materials and Methods: A case-control study was carried out on 120 women (46 patients with histologically confirmed cervical precancerous lesions and 74 healthy controls). The significance of serum selected tumor markers in early detection of cervical intraepithelial neoplasia (CIN) were assessed. Results: Of the case group, the rates of CIN I, II, III, was 69.6%, 23.9%, and 6.5%, respectively. According to the manufacturer's cut-off values of 2ng/ml, 5ng/ml, and 70 U/ml for SCC-Ag, CEA and TPA tests, in that order, SCC-Ag test had a sensitivity of 13%, but CEA and TPA tests could not distinguish between case and control groups. The diagnostic sensitivities were highest at cut-off values of 0.55 ng/ml for SCC-Ag, 2.6ng/ ml for CEA, and 25.5 U/ml for TPA which were 93%, 61%, and 50%, respectively. However, the area under the receiver operating characteristic curve was the largest for SCC-Ag (0.95 vs. 0.61 and 0.60 for CEA and TPA, respectively). Moreover, there was a highly significant direct correlation between SCC-Ag concentration and the degree of cervical precancerous lesions (r=0.847, p<0.001). Conclusions: The new cutoff of 0.5 for SCC-Ag test might be useful as a tumor marker in Iranian patients with CIN and it needs to be more evaluated by studies with larger populationa.

The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease

“…Adopting individual cutoff points based on the ROC curve is important because it can increase sensitivity. This approach, in turn, may increase the chance of detecting precancerous states and enable earlier detection of recurrence [ 13 – 17 ].…”

Prevalence of human papillomavirus infection among Iranian women using COBAS HPV DNA testing

“…Cervical cancer is the third most common gynecologic cancer and the fourth leading cause of cancer death among women worldwide [ 1 ]. It has been demonstrated that persistent infection with high risk human papilloma virus (HR HPV) types playsa major role in the development of cervical intraepithelial neoplasia and cervical cancer [ 2 – 6 ].…”

MicroRNA-466 with tumor markers for cervical cancer screening

“…However, the same tumors can express several different unique antigens [ 13 , 14 ]. Recently, normal cervical cells have been reported to synthesize and secrete the tumor marker carcinoembryonic antigen (CEA) as a frequent constituent of normal cervical mucus [ 15 ]. The cancer antigen 125 (CA125), a transmembranes glycoprotein, is a tumor marker mainly utilized for the diagnosis and treatment of epithelial ovarian cancer and cervical cancer [ 16 ].…”